COVID-19 Clinical Trial
— ISACS-COVID-19Official title:
International Survey of Acute Coronavirus Syndromes (ISACS)-COVID-19
In response to the COVID-19 crisis, ISACS-TC has promoted a new registry of the existing and further centers of the same geographic areas to support clinical research to prevent, and treat the COVID-19 illness. These efforts are made possible by the generous contributions of clinical research volunteers in some of the countries participating to the prior acute coronary syndrome network.
Status | Recruiting |
Enrollment | 10000 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age =18 years (male or female) - Patients admitted to any hospital center with a confirmed diagnosis of COVID-19 infection. Exclusion Criteria: • Underage or not able to give informed consent |
Country | Name | City | State |
---|---|---|---|
Italy | University of Bologna | Bologna | |
Spain | IR-Hospital de la Santa Creu i Sant Pau, UAB | Barcelona |
Lead Sponsor | Collaborator |
---|---|
University of Bologna | Associazione Per La Ricerca Cardiologica (Roma) |
Italy, Spain,
Bugiardini R, Nava S, Caramori G, Yoon J, Badimon L, Bergami M, Cenko E, David A, Demiri I, Dorobantu M, Fronea O, Jankovic R, Kedev S, Ladjevic N, Lasica R, Loncar G, Mancuso G, Mendieta G, Milicic D, Mjehovic P, Pasalic M, Petrovic M, Poposka L, Scarpone M, Stefanovic M, van der Schaar M, Vasiljevic Z, Vavlukis M, Vega Pittao ML, Vukomanovic V, Zdravkovic M, Manfrini O. Sex differences and disparities in cardiovascular outcomes of COVID-19. Cardiovasc Res. 2023 May 22;119(5):1190-1201. doi: 10.1093/cvr/cvad011. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Death all cause | Occurrence of all cause death | 30-day | |
Primary | Death all cause | Occurrence of all cause death | 6 month | |
Primary | Death all cause | Occurrence of all cause death | 12-month | |
Secondary | Heart failure | Occurrence of heart failure or worsening of preexisting heart failure (According to the attending physician) | 30 day, 6 -12 months | |
Secondary | Worsening renal function | Occurrence of kidney disease or worsening of preexisting kidney failure (According to the attending physician) | 30 day, 6 -12 months | |
Secondary | Respiratory Insufficiency | Occurrence of respiratory insufficiency or worsening of preexisting respiratory insufficiency (According to the attending physician) | 30 day, 6 -12 months | |
Secondary | Pneumonia | Occurrence of pneumonia (According to the attending physician) | 30 day, 6 -12 months | |
Secondary | Sepsis | Occurrence of sepsis (According to the attending physician) | 30 day, 6 -12 months | |
Secondary | Systemic Inflammatory Response Syndrome (SIRS) | Occurrence of SIRS (According to the attending physician) | 30 day, 6 -12 months | |
Secondary | Thrombosis (arterial, venous) | Occurrence of thrombosis and thromboembolism (According to the attending physician) | 30 day, 6 -12 months | |
Secondary | Clinically relevant bleeding | Occurrence of clinically relevant bleeding (According to the attending physician) | 30 day, 6 -12 months | |
Secondary | Activity Daily Living status | (According to the attending physician) | 30 day, 6 -12 months | |
Secondary | Depression status | (According to the attending physician) | 30 day, 6 -12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|